Treats spasticity. ANDA 208622, held by Zydus Pharmaceuticals (USA). Tizanidine Hydrochloride.
As of Nov 21, 2026, ANDA 208622 (Tizanidine Hydrochloride), held by Zydus Pharmaceuticals (USA), was first approved by FDA on Mar 3, 2017, with 2 approved supplements and 0 published complete response letters.
Tizanidine capsules are a central alpha-2-adrenergic agonist indicated for the treatment of spasticity. Tizanidine capsules are indicated for the treatment of spasticity in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 3, 2017 | Original application | Approved | None posted |
| Tizanidine HydrochlorideEQ 2MG BASE · capsule;oral | Tizanidine Hydrochloride | Rx |
| Tizanidine HydrochlorideEQ 4MG BASE · capsule;oral | Tizanidine Hydrochloride | Rx |
| Tizanidine HydrochlorideEQ 6MG BASE · capsule;oral | Tizanidine Hydrochloride | Rx |
| Nov 25, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| May 25, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 3, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters